Lurbinectedin is a chemotherapy medicine used to treat small cell lung cancer (SCLC) that has returned after initial treatment. Small cell lung cancer is an aggressive form of lung cancer. Although it often responds well to first-line chemotherapy, the cancer commonly comes back. When this happens, treatment options become more limited.
Lurbinectedin was approved by the U.S. Food and Drug Administration (FDA) in 2020 for adults whose small cell lung cancer has progressed after platinum-based chemotherapy. It is considered a second-line treatment.
Raed About Small Cell Lung Cancer on OncoDaily
How Does Lurbinectedin Work?
Cancer cells grow quickly because they constantly read and use genetic instructions inside their DNA. This process is called transcription. Lurbinectedin works by binding to DNA inside cancer cells and blocking this transcription process. When cancer cells can no longer properly read their genetic instructions, they are less able to survive and multiply.
In addition to directly damaging cancer cells, lurbinectedin may also affect the tumor’s surrounding environment by reducing certain supportive immune cells that help tumors grow.
Who May Receive Lurbinectedin?
Lurbinectedin is used in adults with metastatic small cell lung cancer whose disease has progressed after platinum-based chemotherapy. Doctors consider several factors before recommending it, including how long the cancer responded to first treatment, overall health status, blood counts, and liver function.
For patients whose cancer returned after a longer period of response to first treatment, outcomes with lurbinectedin tend to be somewhat better than in those whose cancer returned quickly.
How Is the Treatment Given?
Lurbinectedin is given as an intravenous (IV) infusion in a clinic or hospital setting. The medication is administered once every three weeks. Each infusion usually lasts about one hour.
Before each treatment cycle, blood tests are performed to ensure blood cell counts and liver function are at safe levels. Treatment continues as long as the cancer remains controlled and side effects are manageable.
How Effective Is Lurbinectedin?
In clinical studies involving patients with relapsed small cell lung cancer, about one-third of patients experienced meaningful tumor shrinkage. In those whose cancer had previously responded well to chemotherapy and then relapsed after several months, response rates were even higher.
Median overall survival in the key clinical study was approximately nine months. While lurbinectedin is not a cure, it can slow disease progression and help control symptoms in many patients.
What Are the Possible Side Effects?
Like most chemotherapy drugs, lurbinectedin can cause side effects. The most common effects involve the blood. Many patients develop low white blood cell counts, which can increase the risk of infection. For this reason, regular blood monitoring is essential. Some patients may require medications to stimulate white blood cell production.
Other common side effects include fatigue, nausea, anemia, and low platelet counts. In some cases, fever may occur, especially if white blood cell counts drop significantly. Patients should immediately report fever, chills, or signs of infection.
Liver enzyme elevations may also occur, which is why liver function is monitored during treatment. Most side effects can be managed with dose adjustments, supportive medications, or temporary treatment delays.
How Does It Compare to Other Options?
For many years, topotecan was the primary second-line therapy for small cell lung cancer. Lurbinectedin offers similar or improved tumor response rates and is often considered easier to tolerate for some patients.
The choice between treatments depends on individual factors, including prior response to chemotherapy, overall health, and physician judgment.
What Should Patients Expect?
Treatment with lurbinectedin is typically outpatient, meaning hospitalization is not usually required. Regular clinic visits and blood tests are part of the treatment routine.
Some patients experience disease stabilization or tumor shrinkage, while others may have limited benefit. Because small cell lung cancer is aggressive, doctors often monitor response closely with imaging scans.
It is important for patients to communicate openly with their oncology team about side effects, symptoms, and concerns during treatment.
Read About Lung Cancer Cure Rate on OncoDaily
Ongoing Research
Researchers continue to study lurbinectedin in combination with immunotherapy and other treatments. The goal is to improve outcomes further in small cell lung cancer, which remains one of the most challenging lung cancers to treat.
Read More Here
Written by Armen Gevorgyan, MD